Panelists share that despite initial emotional challenges, multiple myeloma treatment with targeted combination therapies was ...

The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of bortezomib, ...

The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment ...

Most Oncologic Drugs Advisory Committee members took issue with the lack of dosing optimization and the lack of US patient ...

The results showed that the median time to first diabetic macular oedema resolution in the DEX group was 9.0 months [95% CI: ...

The comeback story of belantamab mafodotin (Blenrep) hit a roadblock Thursday as the FDA's Oncologic Drugs Advisory Committee ...

GSK (GSK) stock slips as FDA advisors vote against the approval of a combination regimen involving thecompany's blood cancer drug Blenrep. Read more here.

The U.S. Food and Drug Administration's panel of independent advisers voted on Thursday against approval of GSK's blood ...

Learn more about dexamethasone dosage, including available strengths, forms, and how it's taken.

Dexamethasone is used to treat many different conditions involving inflammation. Find out about recommended dosages, how to take the drug, and more.